Academic papers demonstrate what is initially possible but do not produce commercializable products. At ARPA-H, leadership engaged final users from project inception so market demand existed upon completion, preventing breakthroughs from remaining trapped in originating laboratories.
Evaluating billions of drug designs computationally does not translate to clinical therapies if wet-lab execution remains constrained. The industry pipeline stalls because assay transfers between laboratories and manufacturing scale-ups still lack physical automation to keep pace with algorithmic discovery.
Traditional protocols and lab notebooks omit embodied habits, such as tube-inverting techniques or tube pre-labeling. Because these unwritten procedural nuances compound across hours of experimentation, undocumented physical variations regularly trigger experimental failures that scientists cannot diagnose.
Automated laboratory setups suffer high failure rates from human operators loading plates incorrectly rather than robotic malfunctions. Because monitoring cameras focus primarily on the machinery, unobserved manual handoffs remain an overlooked vulnerability in autonomous workflows.
Focusing life science AI on narrow domains like biologics manufacturing restricts cross-disciplinary utility. Because molecular biology fundamentally reduces to moving liquids between vessels, models trained on atomic actions can generalize widely and flag physical deviations like pipette bubbles across diverse workflows.
Strict statutory appointments create operational urgency within research teams. At ARPA-H, framing every two elapsed weeks as consuming one percent of a three-year tenure prevented bureaucratic delays and drove teams to pursue immediate, active experimentation.
